Cite
HARVARD Citation
Kremer, J. et al. (n.d.). FRI0167 Patient-Reported Outcomes (PROS) During Treatment with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GM–CSFR-Alpha, In the Phase IIB Earth Explorer 1 Study. Annals of the rheumatic diseases. pp. 483-484. [Online].